You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 金斯瑞生物科技(1548.HK)大漲超15% 附屬療法加速評估申請獲EMA接受
格隆匯 02-02 14:23
格隆匯2月2日丨金斯瑞生物科技(1548.HK)漲幅擴大至15.23%,報11.8港元,暫成交2億港元,總市值230.5億港元。金斯瑞生物科技2月1日公佈,非全資附屬傳奇生物獲EMA(歐洲藥品管理局)CHMP(人用藥品委員會)接受了對在研的靶向B細胞成熟抗原(BCMA)的嵌合抗原受體T細胞療法西達基奧侖賽(cilta-cel)的上市許可申請進行加速評估的請求。公司認為,加速評估的要求獲接受是對cilta-cel在治療多發性骨髓瘤患者中的潛在用途的重要證明。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account